Shin Nippon Biomedical Laboratories, Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2021
November 02, 2021 at 02:00 am EDT
Share
Shin Nippon Biomedical Laboratories, Ltd. reported consolidated earnings results for the six months ended September 30, 2021. For the period, the company reported revenue of ?7,961 million against ?7,003 million a year ago. Operating profit was ?1,969 million against ?1,161 million a year ago. Profit attributable to owners of parent was ?3,503 million against ?1,139 million a year ago. Basic earnings per share was ?84.15 against ?27.36 a year ago.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 
